2012. szeptember 27., csütörtök
Heart failure highlights in 2011
Heart failure highlights in 2011:
Heart failure (HF) remains a major medical problem, and the European Journal of Heart Failure is dedicated to publishing research further investigating its pathophysiology and diagnosis in order to help clinicians alleviate symptoms and improve patient outcomes. 1 This review reports on important studies in the field of HF published in 2011. All research areas are addressed, including experimental studies, biomarkers, clinical trials, arrhythmias, and new insights into the role of device therapy.
Heart failure (HF) remains a major medical problem, and the European Journal of Heart Failure is dedicated to publishing research further investigating its pathophysiology and diagnosis in order to help clinicians alleviate symptoms and improve patient outcomes. 1 This review reports on important studies in the field of HF published in 2011. All research areas are addressed, including experimental studies, biomarkers, clinical trials, arrhythmias, and new insights into the role of device therapy.
2012 ACCF/AHA Focused Update of the Guideline for the Management of Patients With Unstable Angina/Non-ST-Elevation Myocardial Infarction (Updating the 2007 Guideline and Replacing the 2011 Focused Update): A Report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines [ACCF/AHA Focused Update]
World Health Organization Pulmonary Hypertension Group 2: Pulmonary hypertension due to left heart disease in the adult—a summary statement from the Pulmonary Hypertension Council of the International Society for Heart and Lung Transplantation
World Health Organization Pulmonary Hypertension Group 2: Pulmonary hypertension due to left heart disease in the adult—a summary statement from the Pulmonary Hypertension Council of the International Society for Heart and Lung Transplantation: Pulmonary hypertension associated with left heart disease is the most common form of pulmonary hypertension encountered in clinical practice today. Although frequently a target of therapy, its pathophysiology remains poorly understood and its treatment remains undefined. Pulmonary hypertension in the context of left heart disease is a marker of worse prognosis and disease severity, but whether its primary treatment is beneficial or harmful is unknown. An important step to the future study of this important clinical problem will be to standardize definitions across disciplines to facilitate an evidence base that is interpretable and applicable to clinical practice. In this current statement, we provide an extensive review and interpretation of the current available literature to guide current practice and future investigation. At the request of the Pulmonary Hypertension (PH) Council of the International Society for Heart and Lung Transplantation (ISHLT), a writing group was assembled and tasked to put forth this document as described above. The review process was facilitated through the peer review process of the Journal of Heart and Lung Transplantation and ultimately endorsed by the leadership of the ISHLT PH Council.
Small RNA Biomarkers Come of Age⁎
Small RNA Biomarkers Come of Age⁎: MicroRNAs (miRNAs) are endogenous, 21- to 23-nucleotide- long RNA molecules that post-transcriptionally regulate target genes. miRNAs interact specifically with certain mRNAs by repressing their translation or inducing their degradation (1). Current estimates are that miRNAs thereby regulate the levels of the majority of mammalian proteins (2). Research in recent years has assigned miRNAs a key regulatory role in various physiological processes. Also, a growing number of miRNAs has been implicated in the pathogenesis of several diseases, including cardiac disease (3). With respect to the latter, miRNAs have been implicated in cardiac hypertrophy (4,5), fibrosis (6), and vascular disease (7). Intriguingly, miRNAs also appear to represent valid therapeutic targets, because modulation of their expression in vivo (for example, with antisense RNA molecules) has been shown to effectively modulate cardiovascular disease in various animal models (4,6,8–10). Most recently, miRNAs have received much attention regarding their suitability as biomarkers for disease. Following pioneering work from the cancer field (11,12), also several cardiovascular studies have found marked deregulation of miRNAs in various types of clinical specimens (for review, see ref. 13).
ACCF/ACR/AIUM/ASE/ASN/ICAVL/SCAI/SCCT/SIR/SVM/SVS 2012 Appropriate Use Criteria for Peripheral Vascular Ultrasound and Physiological Testing Part I: Arterial Ultrasound and Physiological Testing A Report of the American College of Cardiology Foundation Appropriate Use Criteria Task Force, American College of Radiology, American Institute of Ultrasound in Medicine, American Society of Echocardiography, American Society of Nephrology, Intersocietal Commission for the Accreditation of Vascular Laboratories, Society for Cardiovascular Angiography and Interventions, Society of Cardiovascular Computed Tomography, Society for Interventional Radiology, Society for Vascular Medicine, and Society for Vascular Surgery
Feliratkozás:
Bejegyzések (Atom)